Ariad’s (ARIA)
drug Taltorvic (ridaforolimus) is a novel small-molecule inhibitor of the protein mTOR interferes with cell
growth, division, metabolism and angiogenesis. The FDA
independent committee will discuss, debate and decide whether this drug should,
or should not be approved for metastatic soft tissue sarcoma or bone sarcoma
whose disease has not progressed after at least 4 cycles of chemotherapy.
Agenus (AGEN) has outperformed. Of course some profit-taking was
expected, but the firm has definitely done a good job rebuilding a new pipeline
backed by updated information and more mature understanding of the immune
system and the requirements for a successful immunotherapy. Investors might
have been missing the transformation but when they got the chance to look
deeper into the firm’s programs, they liked what they saw. AGEN’s price has more than doubled since
January 2012 on large trading volume, insinuating that the rally is for real
and that investors are expecting good news to finally emerge from the firm’s
labs and finances in the same time. A relevant comforting symptom is that
Agenus’ partnership with GlaxoSmithKline (GSK) has proven solid like a rock,
which might have helped convince the skeptics that Agenus’ QS-21 Stimulon is
genuine adjuvant essential for to the efficacy of vaccines both preventive and
therapeutic.
In chronic debilitating diseases, improved therapeutics are those state-of-the-art drugs that control the devastating symptoms and limit, or prevent disease progression without causing other pathologies through the treatments’ adverse effects. More...
Hepatitis C virus (HCV) treatments are moving stocks of HCV developers up and down in a chaotic way that makes no sense. While Vertex’ (VRTX) Incivek sales have been breaking the record of drug sales, investors who have been fed immature and unconfirmed knowledge that Pharmasset’s oral HCV therapeutics combination will render Incivek obsolete caused a selloff in VRTX. Investors logic that patients would definitely prefer all oral drugs over a combination that has injectable alfa interferon is undisputable, that’s we too are waiting for a successful all oral HCV treatment, which has yet to emerge. More...
1